Each issue of Pharma Business Daily newsletter majors on stories giving you the edge on: Future Prospects for the Pharmaceutical Industry; Emerging Opportunities in international markets; Latest Strategies for increasing market share before your competitors do; Evolving Regulatory Restrictions that are shaping your market and how to overcome them; and Key Technologies that your competitors are taking advantage of ....and more.
To claim your 10-day FREE trial e-mail us here!
Recent Headlines:
Monday, 19th March, 2007
P H A R M A
M A R K E T
H E A D L I N E S
1.
FDA issues safety alert on Pfizer's Zyvox
2.
Alexion in the money as the FDA backs Soliris
3.
France recommends Gardasil vaccine for 14 year-olds
4.
Cancer Drugs: Postponing death and the invisible Hand
5.
Sanofi's Acomplia to replace Xenical as Standard for the treatment of Obesity by 2010
6.
OrthoDerm enters phase IIb clinical testing
7.
WellPoint expands GenericSelect program to include generic version of Zocor
8.
CytRx announces global RNAi Licensing agreement with Cold Spring Harbor Lab
9.
Viropro enters into contract for the development of monoclonal antibody
10.
AtheroGenics announces ARISE trial results for AGI-1067
11.
Nymox announces positive results from complete Study Of NX-1207 For BPH
12.
ACADIA announces positive results from ACP-103 Phase II Schizophrenia co-therapy trial
13.
SIGA's smallpox drug candidate administered to critically Ill human patient
14.
Beijing Med-Pharma signs agreement for acquisition 70pc interest in Rongheng Pharma
15.
Shire announces expiration of Hart-Scott-Rodino waiting period
16.
NIR Diagnostics receives $550,000 from licensee
17.
Memory Pharma secures $10 million debt financing
18.
Fulcrum Pharma announces placing
19.
DATATRAK prices private placement
20.
NorDiag completes acquisition of Genpoint
21.
Chelsea Therapeutics announces $12.5 million equity financing
22.
Symbollon Pharma initiates carcinogenicity study for IoGen
23.
"Gene therapy for foetuses" hope
24.
GSK's Advair disappoints in new COPD study
25.
Study - Glucerna helps reduce key metabolic markers in overweight patients with type II diabetes
Tuesday, 20th March, 2007
P H A R M A
M A R K E T
H E A D L I N E S
1.
Med Gen newest Product fabulust enters sex enhancement market
2.
Shire launches new bowel disorder drug Lialda in USA
3.
Ranbaxy reportedly drops Merck Buyout Bid
4.
GSK invests $13 million for new Singapore lab
5.
EMEA cuts assessment times as applications flood in
6.
Takeda seeks approval for sleep drug in Europe
7.
Thailand risks losing investments from U.S on Patents Dispute
8.
Talecris initiates clinical program to evaluate aPAO
9.
Cell Therapeutics files for SPA for XYOTAX lung cancer trial in
women
10.
Sinclair Pharma Receives EU Approval for Decapinol
11.
MGI Announces Positive Results from a Phase III Study of Aquava
Injection during Bronchoscopy
12.
Viacell announces commencement of ViaCyte pivotal trial
13.
3SBio announces addition to product portfolio
14.
Dharma Shows IDDS is effective in reducing pain in phase II
clinical trial
15.
Avexa Reports Positive Phase IIb Result
16.
PacificHealth Laboratories amends licensing agreement with
Mott's
17.
Chromos and Pain Therapeutics sign cell line engineering
agreement
18.
Verona Pharma announces material transfer agreement with HepMim
Biosciences
19.
La Jolla Pharmaceutical announces proposed public offering of
common stock
20.
ViroPharma announces proposed offering of $200 million in
convertible senior notes
21.
Iwaki signs JPY 6 Billion commitment line contract
22.
MDS completes acquisition of molecular devices
23.
Genetically-engineered mosquito fights malaria
24.
Report-Pharmaceutical Brands Balance Patient Education and DTC
Advertising
25.
Study-Nearly 5 million have Alzheimer's in US
Wednesday, 21st March 2007
P H A R M A
M A R K E T
H E A D L I N E S
1.
Japan issues health alert over Tamiflu
2.
Pfizer's Celebrex patents upheld after Teva challenge
3.
FDA approve Keppra for US epilepsy patients
4.
Diamics receives FDA clearance for cervical sample collection
system
5.
FDA seeks more data on Astellas' Prograf uses
6.
Research finds Leukaemia survivors more prone to other cancers
7.
Emergent BioSolutions files IND application for anthrax
treatment
8.
Study finds antibiotics and steroids overused for sinusitis
9.
Amicus presents positive results from study of Plicera for
Gaucher disease
10.
Study shows bone mineral loss in men after heart surgery
11.
Study suggests schizophrenia may be linked to inflammation
12.
Report warns millions of flu shots to be wasted
13.
Takeda reorganises pharma marketing division in Japan
14.
Schering-Plough announce new NCCN guidelines for Noxafil
antifungal agent
15.
Junk food may increase cancer risk in women
16.
Acambis to test west nile virus vaccine in older adults
17.
FDA extends marketing for Levaquin
18.
AstraZeneca opens global process R&D lab in Bangalore
19.
Study finds bacterial Meningitis during infancy undermines
academic success
20.
BioImagene unveils 3i Platform for image informatics solutions
21.
Study finds obese men with prostate cancer face higher death
risk
22.
ImmuneRegen announces data on Homspera for influenza and cancer
23.
Study finds smoking affects skin all over the body
24.
China's scandal over tea-for-urine samples
25.
Study finds sleep disorder creates 'Mr Hyde'
Thursday, 22nd March, 2007
P H A R M A
M A R K E T
H E A D L I N E S
1.
Japan's Eisai to buy Morphotek for $325 million
2.
GSK's once-a-day Coreg available for the treatment of CV
conditions
3.
ABPI welcomes Brown's Budget commitment to innovation
4.
FDA tackles conflict of interest on advisory panels
5.
Sanofi's Acomplia gets limited French payments
6.
Nycomed to shed 1,250 jobs as part of Altana Pharma integration
7.
PDI losing $35 million a year contract
8.
Eli Lilly announces partnership to fight MDR-TB
9.
Reps ask J&J and Amgen to stop drug ads
10.
US court prohibits Mylan from marketing generic version of Topax
11.
US lawmakers OK $870 million for bird flu vaccine
12.
Aeterna announces positive results with Cetrorelix in BPH for
Japanese phase IIa trial
13.
Merck subsidiary initiates squeeze out procedure for Merck
Serono shares
14.
Arrowhead's Unidym to merge with Carbon Nanotechnologies
15.
Cubist Pharma licenses rights of CUBICIN in Japan to Merck
16.
Edwards Lifesciences sells TMR heart laser distribution rights
to Novadaq
17.
OXIS signs supply agreement with Golden Gourmet mushrooms
18.
PreMD announces private placement
19.
Chromos molecular systems announces bought deal private
placement
20.
Mymetics corporation resolves credit facility and litigation
with MFC merchant bank
21.
Abaxis announces CLIA waived status for two additional medical
test panels
22.
ProMetic and Tecpar sign $19 million technology transfer deal
23.
Bentley Pharma announces approval for Tamulosin in Spain
24.
Microbix wins patent that boosts production of Flu vaccine
25.
Vion Pharma extends manufacturing agreement with SAFC for
Cloretazine
Friday 23rd March, 2007
P H A R M A
M A R K E T
H E A D L I N E S
1.
Astellas expects stronger growth for Eligard in EU
2.
UCB's Cimzia faces severe delay as new study is needed
3.
Zeltia unit heads consortium for major Spanish R&D project
4.
Shire sues Colony and Actavis over Adderall infringement
5.
US Appeals Court reverses decision upholding Pfizer's Norvasc
patent
6.
Procognia enters protein kinase array collaboration with GSK
7.
Feds want more information on generic deals from Cephalon
8.
Pain Therapeutics licenses haemophilia treatment
9.
Torrent Pharma and Teva likely to bag $2 billion business of
Merck
10.
Overhaul needed for first-in-man trials
11.
EU drugs panel says Tamiflu benefits outweigh risks
12.
Prozen announces Trexima amended response accepted for review by
FDA
13.
Par begins shipment of generic Zantac syrup
14.
Genentech sees flat sequential US sales
15.
Gilead's Ambrisentan validated in Europe
16.
Hana Biosciences' shares fall on drug pipeline update
17.
Amgen halts drug trial of Vectibix
18.
Diversa announces pricing of $100 million CSN due 2027
19.
Chelsea Therapeutics completes $12.5 million equity financing
20.
Innogenetics raises EUR31.7 million via CBI
21.
Hi-Tech Pharmacal receives tentative approval for Calcipotriene
topical solution
22.
Integra agrees to buy LXU healthcare
23.
Dalton Pharma and Affectis Pharma enter into a contract
24.
Dermatrends announces anti-psychotic contract with Teikoku
Pharma
25.
Study - Alcohol and tobacco among worst drugs
Monday, 19th March, 2007
P H A R M A
M A R K E T
H E A D L I N E S
1.
FDA issues safety alert on Pfizer's Zyvox
2.
Alexion in the money as the FDA backs Soliris
3.
France recommends Gardasil vaccine for 14 year-olds
4.
Cancer Drugs: Postponing death and the invisible Hand
5.
Sanofi's Acomplia to replace Xenical as Standard for the treatment of Obesity by 2010
6.
OrthoDerm enters phase IIb clinical testing
7.
WellPoint expands GenericSelect program to include generic version of Zocor
8.
CytRx announces global RNAi Licensing agreement with Cold Spring Harbor Lab
9.
Viropro enters into contract for the development of monoclonal antibody
10.
AtheroGenics announces ARISE trial results for AGI-1067
11.
Nymox announces positive results from complete Study Of NX-1207 For BPH
12.
ACADIA announces positive results from ACP-103 Phase II Schizophrenia co-therapy trial
13.
SIGA's smallpox drug candidate administered to critically Ill human patient
14.
Beijing Med-Pharma signs agreement for acquisition 70pc interest in Rongheng Pharma
15.
Shire announces expiration of Hart-Scott-Rodino waiting period
16.
NIR Diagnostics receives $550,000 from licensee
17.
Memory Pharma secures $10 million debt financing
18.
Fulcrum Pharma announces placing
19.
DATATRAK prices private placement
20.
NorDiag completes acquisition of Genpoint
21.
Chelsea Therapeutics announces $12.5 million equity financing
22.
Symbollon Pharma initiates carcinogenicity study for IoGen
23.
"Gene therapy for foetuses" hope
24.
GSK's Advair disappoints in new COPD study
25.
Study - Glucerna helps reduce key metabolic markers in overweight patients with type II diabetes
Friday, 16th March, 2007
P H A R M A
M A R K E T
H E A D L I N E S
1.
Bayer has high hopes that cancer drug Nexavar will be huge
2.
Bayer to create 1,700 new jobs in the near future
3.
Opinion divided as Abbott stops selling new drugs in Thailand
4.
Bristol-Myers pulls $25 billion assets out of Ireland
5.
FDA chief suggests "junior" status for copies of biotech drugs
6.
Endo Pharma announce three-month extension of PDUFA date for Frova sNDA
7.
Merck's vaccine receives all clear from CD
8.
Decision Imminent in Tamoxifen Petition on AstraZeneca, Barr Settlement
9.
MedImmune leases Human Genome facility to expand influenza vaccine manufacturing capabilities
10.
Trimeris and Roche amend deals
11.
Alliance Pharma updates clinical development of Oxygent in China
12.
Sanofi-Aventis cutting 200 jobs in Ireland
13.
Exelixis Files IND Application for XL147
14.
Endo Pharma announces three month extension of PDUFA data for SNDA
15.
Titan Pharma announces equity financing commitment of up to $25 Million
16.
DiagnoCure announces $25,155,000 bought deal
17.
Shandong Shanda announces no dividend payment for FY 2006
18.
NIR Diagnostics receives $550,000 from Licensee
19.
Micromet And TRACON sign license agreement to develop and commercialize D93
Each issue of Pharma Business Daily newsletter majors on stories giving you the edge on: Future Prospects for the Pharmaceutical Industry; Emerging Opportunities in international markets; Latest Strategies for increasing market share before your competitors do; and more!